Eudra GMP - Public Layout

MIA | GMP | API REG | WDA | GDP | Sites

Help

Tue 10 Nov 2026 15:23:30 BST

GMP Compliance Menu

GMP Certificates

Non-Compliance Report

The Certificate has been invalidated, invalidated date is : 2026-01-15

Print Preview

Print Preview (Short version)

Back To Search

National Organization For Medicines

CERTIFICATE NUMBER: 148670,154329/ 19-12-2025

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 111(5) of Directive 2001/83/EC as amended
Art. 15 of Directive 2001/20/EC as amended

The competent authority of Greece confirms the following:

The manufacturer: Pharmathen International S.A.

Site address:

Block No 5, Sapes Rodopi Prefecture, Industrial Park, Sapes, 693 00, Greece

OMS Organisation Id. / OMS Location Id.: ORG-100043114 / LOC-100072733

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. 0000007311/26/1 in accordance with Art. 13 of Directive 2001/20/EC and Art. 40 of Directive 2001/83/EC, transposed in the following national legislation:ΔΥΓ 3/89292/03, Art. 12 and Δ.ΥΓ 3(α)/Γ.Π. 32221/29-4-2013, art. 57.

Other

(Human) -

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2024-12-20 , it is considered that it complies with:

The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2. (3)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

__________________________________________________________________________________________________________________________

(1) The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC and Art. 15 of Directive 2001/20/ECis also applicable to importers.
(2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
(3) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products
Human Investigational Medicinal Products

1 MANUFACTURING OPERATIONS

1.2 Non-sterile products

   1.2.1  Non-sterile products (processing operations for the following dosage forms)
           1.2.1.1  Capsules, hard shell
           1.2.1.8  Other solid dosage forms: Powder for oral suspension(en)
           1.2.1.13  Tablets
   1.2.2  Batch certification

1.5 Packaging

   1.5.1  Primary Packaging
           1.5.1.1  Capsules, hard shell
           1.5.1.2  Capsules, soft shell
           1.5.1.8  Other solid dosage forms: Powder for oral suspension(en)
           1.5.1.13  Tablets
   1.5.2  Secondary packaging

1.6 Quality control testing

   1.6.1  Microbiological: sterility
   1.6.2  Microbiological: non-sterility
   1.6.3  Chemical/Physical
   1.6.4  Biological

2 IMPORTATION OF MEDICINAL PRODUCTS

2.1 Quality control testing of imported medicinal products

   2.1.1  Microbiological: sterility
   2.1.2  Microbiological: non-sterility
   2.1.3  Chemical/Physical
   2.1.4  Biological

2.2 Batch certification of imported medicinal products

   2.2.1  Sterile products
           2.2.1.1  Aseptically prepared
           2.2.1.2  Terminally sterilised

2.3 Other importation activities

2.3.1 Site of physical importation

Clarifying remarks (for public users):

A) 1.6 Quality Cintrol: Under Biological controls only LAL test is performed. B) Storage of pharmaceutical starting materials, packaging materials and finished products for human use in the warehouse located in Industrial Park Sapes Rodopi Prefecture, Block No 6, Rodopi, C) Import from Third Countries of Sterile Active Pharmaceutical Ingredient (API) in the form of: Powder, D) Storage of pharmaceutical raw materials, packaging materials, intermediate and finished pharmaceutical products for human use in a warehouse of the company PHARMATHEN A.B.E.E., located at Melissia Site, Aspropyrgos, Attiki, Greece.

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.